



ANDA 203263

Caraco Pharmaceutical Laboratories Ltd.
U.S. Agent for: Sun Pharma Global FZE
Attention: Robert Kurkiewicz
Director, Regulatory Affairs
1150 Elijah McCoy Drive
Detroit, MI 48202

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated June 16, 2011, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Doxorubicin Hydrochloride Liposome Injection USP, 2 mg/mL, packaged in 20 mg/10 mL and 50 mg/25 mL Single-use Vials.

Reference is also made to your amendments dated November 3, 2011; March 7, March 20, April 9, May 10, June 29, July 4, July 5, July 27, August 4, September 26, October 5, and December 20, 2012; and January 21, 2013.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Doxorubicin Hydrochloride Liposome Injection USP, 2 mg/mL, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug product (RLD), Doxil[®] Liposome Injection, 2 mg/mL, of Janssen Research and Development, LLC. Your drug release testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

{See appended electronic signature page}

Gregory P. Geba, M.D., M.P.H.
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST

02/04/2013

Deputy Director, Office of Generic Drugs, for
Gregory P. Geba, M.D., M.P.H.